微气泡
药物输送
血栓
溶栓
组织纤溶酶原激活剂
生物医学工程
医学
溶栓药
超声波
血栓形成
渗透(战争)
靶向给药
药理学
药品
材料科学
心脏病学
内科学
纳米技术
放射科
心肌梗塞
工程类
运筹学
作者
Siyu Wang,Xixi Guo,Weijun Xiu,Yang Liu,Lili Ren,Huaxin Xiao,Fang Yang,Yu Gao,Chenjie Xu,Lianhui Wang
出处
期刊:Science Advances
[American Association for the Advancement of Science]
日期:2020-07-29
卷期号:6 (31): eaaz8204-eaaz8204
被引量:209
标识
DOI:10.1126/sciadv.aaz8204
摘要
Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator (tPA) are challenged by the low bioavailability, off-target side effects and limited penetration in thrombi, leading to delayed recanalization. We hypothesize that these challenges can be addressed with the targeted and controlled delivery of thrombolytic drugs or precision drug delivery. A porous and magnetic microbubble platform is developed to formulate tPA. This system can maintain the tPA activity during circulation, be magnetically guided to the thrombi, and then remotely activated for drug release. The ultrasound stimulation also improves the drug penetration into thrombi. In a mouse model of venous thrombosis, the residual thrombus decreased by 67.5% when compared to conventional injection of tPA. The penetration of tPA by ultrasound was up to several hundred micrometers in thrombi. This strategy not only improves the therapeutic efficacy but also accelerates the lytic rate, enabling it to be promising in time-critical thrombolytic therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI